Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”) based therapeutics and wellness products, today announced its initiation of an exploratory clinical study of CaniDermRx. Jupiter’s prescription topical cream candidate, CaniDermRx, combines CBD and aspartame as its active ingredients in the treatment of first degree burns. While, to Jupiter’s knowledge, no double-blind, randomized controlled study has demonstrated efficacy of a CBD-aspartame product in the treatment of burns, CaniDermRx may be effective in this indication based on its dual mechanisms of action. “We are pleased to commence this clinical study in what is now our second indication for our CBD-based prescription therapeutic candidate CaniDermRx,” said Jupiter CEO Brian John. “As the number of burn cases is increasing worldwide, we are eager to explore the healing potential of CaniDermRx’s dual mechanisms of action for this patient population. Data resulting from the study would be included in an Investigational New Drug (‘IND’) application that we intend to file with the FDA for Phase I or II studies in the U.S.”
To view the full press release, visit https://ibn.fm/mWu4U
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”) based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For more information, visit the company’s website at www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.